Redmile Group, LLC Prothena Corp Public LTD CO Transaction History

Redmile Group, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$25.16 - $60.63 $5.3 Million - $12.8 Million	-210,600 Reduced 28.61%	525,575 $31.9 Million
Q1 2022 May 16, 2022	SELL	$30.27 - $49.22 $892,965 - $1.45 Million	-29,500 Reduced 3.85%	736,175 $26.9 Million
Q4 2021 Feb 14, 2022	SELL	$42.11 - $73.26 $5.72 Million - $9.95 Million	-135,816 Reduced 15.07%	765,675 $37.8 Million
Q3 2021 Nov 15, 2021	SELL	$48.2 - $78.89 $15.1 Million - $24.8 Million	-314,166 Reduced 25.84%	901,491 $64.2 Million
Q2 2021 Aug 16, 2021	SELL	$21.63 - $57.65 $13.9 Million - $37 Million	-641,415 Reduced 34.54%	1,215,657 $62.5 Million
Q1 2021 May 17, 2021	BUY	$11.0 - $28.24 $20.4 Million - $52.4 Million	1,857,072 New	1,857,072 $46.7 Million

184

42.7M

162K

102K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $714M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Redmile Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Redmile Group, LLC with notifications on news.